Who is sponsoring NCT05367713?

NCT05367713 is sponsored by Hospices Civils de Lyon.

What drugs are being tested in NCT05367713?

Interventions in NCT05367713: patients having had an osteitis of the cranial flap after craniectomy.

What condition does NCT05367713 study?

NCT05367713 studies Osteitis, Cranial Flap.

Is NCT05367713 still recruiting?

NCT05367713 is currently status unknown. Last updated 10 May 2022.

Last reviewed 2022-05-10 · How we verify

NCT05367713: BoFOC

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Bone Flap Osteomyelitis Following Craniectomy : Retrospective Evaluation of Clinical Presentation, Microbiological Diagnosis and Management

Status unknown Last updated 10 May 2022

What this trial tests

trial testing patients having had an osteitis of the cranial flap after craniectomy in Osteitis in 160 participants. Status unknown.

Timeline

1 April 2022

Primary endpoint
1 May 2022

1 June 2022

Quick facts

Lead sponsor	Hospices Civils de Lyon
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	160
Start date	1 April 2022
Primary completion	1 May 2022
Estimated completion	1 June 2022
Sites	1 location across France

Drugs / interventions tested

patients having had an osteitis of the cranial flap after craniectomy

Conditions studied

Osteitis — all drugs for Osteitis →
Cranial Flap — all drugs for Cranial Flap →

Sponsor

Hospices Civils de Lyon — full company profile →

Who can join

18 and older, any sex, with Osteitis or Cranial Flap. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Osteitis of the cranial flap after craniectomy is an unknown complex osteoarticular infection and there are few data concerning its epidemiology, its risk factors, and its management.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Hospices Civils de Lyon trials

Trials by the same sponsor.

NCT07569536 — Efficacy of the Alpha 2 Agonist Dexmedetomidine for Sympathetic Deactivation in REfractory Septic Shock · Phase 3 · not yet recruiting
NCT07529314 — Evaluating Interventional Radiology for Cancer Pain Management · NA · not yet recruiting
NCT07273929 — Comparative Study of the Effectiveness of Three Access Routes for Implanting an Electronic Intracardiac Device · Phase 3 · not yet recruiting
NCT07474532 — Attitudes and Beliefs Related to Benzodiazepine Deprescribing · not yet recruiting
NCT07313007 — Assessment of Gut Microbiota-Derived Amino Acid Metabolite Production in Patients With MASLD · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05367713 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hospices Civils de Lyon
Last refreshed: 10 May 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05367713.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing